
Sign up to save your podcasts
Or


From CAR-T therapies to viral vectors, cell and gene treatments are redefining the boundaries of pharmacy practice—but with innovation comes complexity. Host Carolyn Liptak welcomes Dr. Mark Wiencek, Principal Microbiologist with the Technical Services Group at Contec, and Dr. Amanda Frick, Senior Clinical Manager of Market Intelligence at Vizient, to break down the challenges of compounding these advanced therapies.
Listen in as they discuss real-world risk assessments, biosafety considerations, and how hospital pharmacies can safely manage these groundbreaking yet high-risk treatments.
Guest speakers:
Mark Wiencek, PhD
Contec
Amanda Frick, PharmD, BCPS
Host:
Carolyn Liptak, MBA, RPh
Pharmacy Executive Director
Vizient
Show Notes:
[01:02-01:51] Mark shares his background and experience in microbiology
[01:52-04:04] Overview of the types of cell and gene therapies (CGT) currently used in clinical practice
[04:05-05:14] Which CGT therapies are most applicable to pharmacy compounding and why
[05:15-10:29] Things not on the NIOSH list and the risks
[10:30-12:03] Evaluating whether viral vectors can penetrate intact skin and the true occupational exposure risks
[12:04-13:18] If hazards are not defined by the NIOSH list, how should these CGT hazards be classified
[13:19-15:03] Determining the safest environment for compounding CGT therapies
[15:04-20:14] Best practices for decontamination, disinfection, and viral vector handling
[20:15-20:59] Do you need a dedicated biosafety cabinet for CGT therapies
[21:00-22:55] Recommended resources for further learning
Links | Resources:
VerifiedRx Listener Feedback Survey:
We would love to hear from you - Please click here
Subscribe Today!
Apple Podcasts
Spotify
YouTube
RSS Feed
By Vizient Center for Pharmacy Practice Excellence4.6
99 ratings
From CAR-T therapies to viral vectors, cell and gene treatments are redefining the boundaries of pharmacy practice—but with innovation comes complexity. Host Carolyn Liptak welcomes Dr. Mark Wiencek, Principal Microbiologist with the Technical Services Group at Contec, and Dr. Amanda Frick, Senior Clinical Manager of Market Intelligence at Vizient, to break down the challenges of compounding these advanced therapies.
Listen in as they discuss real-world risk assessments, biosafety considerations, and how hospital pharmacies can safely manage these groundbreaking yet high-risk treatments.
Guest speakers:
Mark Wiencek, PhD
Contec
Amanda Frick, PharmD, BCPS
Host:
Carolyn Liptak, MBA, RPh
Pharmacy Executive Director
Vizient
Show Notes:
[01:02-01:51] Mark shares his background and experience in microbiology
[01:52-04:04] Overview of the types of cell and gene therapies (CGT) currently used in clinical practice
[04:05-05:14] Which CGT therapies are most applicable to pharmacy compounding and why
[05:15-10:29] Things not on the NIOSH list and the risks
[10:30-12:03] Evaluating whether viral vectors can penetrate intact skin and the true occupational exposure risks
[12:04-13:18] If hazards are not defined by the NIOSH list, how should these CGT hazards be classified
[13:19-15:03] Determining the safest environment for compounding CGT therapies
[15:04-20:14] Best practices for decontamination, disinfection, and viral vector handling
[20:15-20:59] Do you need a dedicated biosafety cabinet for CGT therapies
[21:00-22:55] Recommended resources for further learning
Links | Resources:
VerifiedRx Listener Feedback Survey:
We would love to hear from you - Please click here
Subscribe Today!
Apple Podcasts
Spotify
YouTube
RSS Feed

32,338 Listeners

113,460 Listeners

23 Listeners

677 Listeners